An investigational pan-RAS inhibitor—daraxonrasib (RMC-6236)—shows early activity and has a manageable safety profile in patients with previously treated RAS-mutant PDAC, according to data presented at the 2025 ASCO Gastrointestinal Cancers...
(External Link)